Equities researchers at Ascendiant Capital Markets assumed coverage on shares of Daxor (NYSEAMERICAN:DXR) in a report issued on Thursday, BenzingaRatingsTable reports. The brokerage set a “buy” rating and a $20.00 price target on the stock. Ascendiant Capital Markets’ target price would suggest a potential upside of 94.55% from the company’s previous close.
Shares of NYSEAMERICAN:DXR opened at $10.28 on Thursday. Daxor has a one year low of $4.30 and a one year high of $19.95.
An institutional investor recently bought a new position in Daxor stock. Shine Investment Advisory Services Inc. bought a new position in shares of Daxor Co. (NYSEAMERICAN:DXR) during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 45,454 shares of the company’s stock, valued at approximately $512,000. Shine Investment Advisory Services Inc. owned 1.22% of Daxor at the end of the most recent quarter.
Daxor Company Profile
Daxor Corporation, a medical device company, provides biotechnology and cryobanking services in the United States. The company offers BVA-100 Blood Volume Analyzer, an instrument that measures blood volume in human body. BVA-100 Blood Volume Analyzer is used to diagnose and treat patients in various medical and surgical conditions, including congestive heart failure, critical care medicine and intensive care unit medicine, hypertension, syncope, pre-operative blood screening for hidden anemia, anemia in cancer patients, kidney failure, and hyponatremia.
Recommended Story: Marijuana Stocks Investing Considerations
Receive News & Ratings for Daxor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daxor and related companies with MarketBeat.com's FREE daily email newsletter.